Recently, a study showed that around 60% of ACCs have high levels of TROP2 expression on IHC, providing the biological rationale for using anti-TROP2 antibody–drug conjugate (ADC) such as Sacituzumab govitecan, widely used in breast cancer and evaluated in HNSCC, as novel potential therapy [161,162]. Here, TACSTD2 is linked to head and neck squamous cell carcinoma.